Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines

Autores
Rossini, Andrés Eugenio; Dagrosa, María Alejandra; Portu, Agustina Mariana; Saint Martin, María Laura Gisela; Thorp, Silvia Inés; Casal, Mariana; Navarro, Aime; Juvenal, Guillermo Juan; Pisarev, Mario Alberto
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Purpose: In order to optimize the effectiveness of Boron Neutron Capture Therapy (BNCT), Relative Biological Effectiveness (RBE) and Compound Biological Effectiveness (CBE) were determined in two human melanoma cell lines, M8 and Mel-J cells, using the amino acid p-boronophenylalanine (BPA) as boron carrier. Materials and methods: The effects of BNCT on the primary amelanotic cell line M8 and on the metastatic pigmented melanoma cell line Mel-J were studied using colony formation assay. The RBE values were determined using both a gamma ray source, and the neutron beam from the Nuclear Reactor of the National Atomic Energy Commission (RA-3). For the determination of the RBE, cells were irradiated with increasing doses of both sources, between 1 and 8 Gy; and for the determination of CBE factors, the cells were pre-incubated with BPA before irradiation. Afterwards, the cell surviving fraction (SF) was determined for each treatment. Results: Marked differences were observed between both cell lines. Mel-J cells were more radioresistant than the M8 cell line. The clonogenic assays showed that for a SF of 1%, the RBE values were 1.3 for M8 cells and 1.5 for Mel-J cells. Similarly, the CBE values for a 1% SF were 2.1 for M8 and 3 for Mel-J cell lines. For the endpoint of 0.1% of SF the RBE values obtained were 1.2 for M8 and 1.4 for Mel-J cells. Finally, CBE values calculated for a 0.1% were 2 and 2.6 for M8 and Mel-J cell lines respectively. In order to estimate the uptake of the non-radioactive isotope Boron 10 (10B), a neutron induced autoradiographic technique was performed showing discrepancies in 10B uptake between both cell lines. Conclusions: These obtained in vitro results are the first effectiveness factors determined for human melanoma at the RA-3 nuclear reactor and show that BNCT dosimetry planning for patients could be successfully performed using these new factors.
Fil: Rossini, Andrés Eugenio. Comisión Nacional de Energía Atómica; Argentina
Fil: Dagrosa, María Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; Argentina
Fil: Portu, Agustina Mariana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; Argentina
Fil: Saint Martin, María Laura Gisela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; Argentina
Fil: Thorp, Silvia Inés. Comisión Nacional de Energía Atómica; Argentina
Fil: Casal, Mariana. Comisión Nacional de Energía Atómica; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina
Fil: Navarro, Aime. Autoridad Regulatoria Nuclear; Argentina
Fil: Juvenal, Guillermo Juan. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; Argentina
Fil: Pisarev, Mario Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana; Argentina
Materia
Boron Neutron Capture Therapy (Bnct)
Relative Biological Effectiveness (Rbe)
Compound Biological Effectiveness (Cbe)
Borophenylalanine
Melanoma
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/35931
Acceder
id CONICETDig_4118f9768ced5b9ee5409f38e13654f9
oai_identifier_str oai:ri.conicet.gov.ar:11336/35931
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell linesRossini, Andrés EugenioDagrosa, María AlejandraPortu, Agustina MarianaSaint Martin, María Laura GiselaThorp, Silvia InésCasal, MarianaNavarro, AimeJuvenal, Guillermo JuanPisarev, Mario AlbertoBoron Neutron Capture Therapy (Bnct)Relative Biological Effectiveness (Rbe)Compound Biological Effectiveness (Cbe)BorophenylalanineMelanomahttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Purpose: In order to optimize the effectiveness of Boron Neutron Capture Therapy (BNCT), Relative Biological Effectiveness (RBE) and Compound Biological Effectiveness (CBE) were determined in two human melanoma cell lines, M8 and Mel-J cells, using the amino acid p-boronophenylalanine (BPA) as boron carrier. Materials and methods: The effects of BNCT on the primary amelanotic cell line M8 and on the metastatic pigmented melanoma cell line Mel-J were studied using colony formation assay. The RBE values were determined using both a gamma ray source, and the neutron beam from the Nuclear Reactor of the National Atomic Energy Commission (RA-3). For the determination of the RBE, cells were irradiated with increasing doses of both sources, between 1 and 8 Gy; and for the determination of CBE factors, the cells were pre-incubated with BPA before irradiation. Afterwards, the cell surviving fraction (SF) was determined for each treatment. Results: Marked differences were observed between both cell lines. Mel-J cells were more radioresistant than the M8 cell line. The clonogenic assays showed that for a SF of 1%, the RBE values were 1.3 for M8 cells and 1.5 for Mel-J cells. Similarly, the CBE values for a 1% SF were 2.1 for M8 and 3 for Mel-J cell lines. For the endpoint of 0.1% of SF the RBE values obtained were 1.2 for M8 and 1.4 for Mel-J cells. Finally, CBE values calculated for a 0.1% were 2 and 2.6 for M8 and Mel-J cell lines respectively. In order to estimate the uptake of the non-radioactive isotope Boron 10 (10B), a neutron induced autoradiographic technique was performed showing discrepancies in 10B uptake between both cell lines. Conclusions: These obtained in vitro results are the first effectiveness factors determined for human melanoma at the RA-3 nuclear reactor and show that BNCT dosimetry planning for patients could be successfully performed using these new factors.Fil: Rossini, Andrés Eugenio. Comisión Nacional de Energía Atómica; ArgentinaFil: Dagrosa, María Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; ArgentinaFil: Portu, Agustina Mariana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; ArgentinaFil: Saint Martin, María Laura Gisela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; ArgentinaFil: Thorp, Silvia Inés. Comisión Nacional de Energía Atómica; ArgentinaFil: Casal, Mariana. Comisión Nacional de Energía Atómica; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; ArgentinaFil: Navarro, Aime. Autoridad Regulatoria Nuclear; ArgentinaFil: Juvenal, Guillermo Juan. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; ArgentinaFil: Pisarev, Mario Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana; ArgentinaTaylor & Francis Ltd2014-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/35931Rossini, Andrés Eugenio; Dagrosa, María Alejandra; Portu, Agustina Mariana; Saint Martin, María Laura Gisela; Thorp, Silvia Inés; et al.; Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines; Taylor & Francis Ltd; International Journal Of Radiation Biology; 91; 1; 8-2014; 81-890955-3002CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3109/09553002.2014.942013info:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/full/10.3109/09553002.2014.942013info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:53:05Zoai:ri.conicet.gov.ar:11336/35931instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:53:05.331CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines
title Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines
spellingShingle Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines
Rossini, Andrés Eugenio
Boron Neutron Capture Therapy (Bnct)
Relative Biological Effectiveness (Rbe)
Compound Biological Effectiveness (Cbe)
Borophenylalanine
Melanoma
title_short Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines
title_full Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines
title_fullStr Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines
title_full_unstemmed Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines
title_sort Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines
dc.creator.none.fl_str_mv Rossini, Andrés Eugenio
Dagrosa, María Alejandra
Portu, Agustina Mariana
Saint Martin, María Laura Gisela
Thorp, Silvia Inés
Casal, Mariana
Navarro, Aime
Juvenal, Guillermo Juan
Pisarev, Mario Alberto
author Rossini, Andrés Eugenio
author_facet Rossini, Andrés Eugenio
Dagrosa, María Alejandra
Portu, Agustina Mariana
Saint Martin, María Laura Gisela
Thorp, Silvia Inés
Casal, Mariana
Navarro, Aime
Juvenal, Guillermo Juan
Pisarev, Mario Alberto
author_role author
author2 Dagrosa, María Alejandra
Portu, Agustina Mariana
Saint Martin, María Laura Gisela
Thorp, Silvia Inés
Casal, Mariana
Navarro, Aime
Juvenal, Guillermo Juan
Pisarev, Mario Alberto
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Boron Neutron Capture Therapy (Bnct)
Relative Biological Effectiveness (Rbe)
Compound Biological Effectiveness (Cbe)
Borophenylalanine
Melanoma
topic Boron Neutron Capture Therapy (Bnct)
Relative Biological Effectiveness (Rbe)
Compound Biological Effectiveness (Cbe)
Borophenylalanine
Melanoma
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Purpose: In order to optimize the effectiveness of Boron Neutron Capture Therapy (BNCT), Relative Biological Effectiveness (RBE) and Compound Biological Effectiveness (CBE) were determined in two human melanoma cell lines, M8 and Mel-J cells, using the amino acid p-boronophenylalanine (BPA) as boron carrier. Materials and methods: The effects of BNCT on the primary amelanotic cell line M8 and on the metastatic pigmented melanoma cell line Mel-J were studied using colony formation assay. The RBE values were determined using both a gamma ray source, and the neutron beam from the Nuclear Reactor of the National Atomic Energy Commission (RA-3). For the determination of the RBE, cells were irradiated with increasing doses of both sources, between 1 and 8 Gy; and for the determination of CBE factors, the cells were pre-incubated with BPA before irradiation. Afterwards, the cell surviving fraction (SF) was determined for each treatment. Results: Marked differences were observed between both cell lines. Mel-J cells were more radioresistant than the M8 cell line. The clonogenic assays showed that for a SF of 1%, the RBE values were 1.3 for M8 cells and 1.5 for Mel-J cells. Similarly, the CBE values for a 1% SF were 2.1 for M8 and 3 for Mel-J cell lines. For the endpoint of 0.1% of SF the RBE values obtained were 1.2 for M8 and 1.4 for Mel-J cells. Finally, CBE values calculated for a 0.1% were 2 and 2.6 for M8 and Mel-J cell lines respectively. In order to estimate the uptake of the non-radioactive isotope Boron 10 (10B), a neutron induced autoradiographic technique was performed showing discrepancies in 10B uptake between both cell lines. Conclusions: These obtained in vitro results are the first effectiveness factors determined for human melanoma at the RA-3 nuclear reactor and show that BNCT dosimetry planning for patients could be successfully performed using these new factors.
Fil: Rossini, Andrés Eugenio. Comisión Nacional de Energía Atómica; Argentina
Fil: Dagrosa, María Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; Argentina
Fil: Portu, Agustina Mariana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; Argentina
Fil: Saint Martin, María Laura Gisela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; Argentina
Fil: Thorp, Silvia Inés. Comisión Nacional de Energía Atómica; Argentina
Fil: Casal, Mariana. Comisión Nacional de Energía Atómica; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina
Fil: Navarro, Aime. Autoridad Regulatoria Nuclear; Argentina
Fil: Juvenal, Guillermo Juan. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; Argentina
Fil: Pisarev, Mario Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Comisión Nacional de Energía Atómica; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana; Argentina
description Purpose: In order to optimize the effectiveness of Boron Neutron Capture Therapy (BNCT), Relative Biological Effectiveness (RBE) and Compound Biological Effectiveness (CBE) were determined in two human melanoma cell lines, M8 and Mel-J cells, using the amino acid p-boronophenylalanine (BPA) as boron carrier. Materials and methods: The effects of BNCT on the primary amelanotic cell line M8 and on the metastatic pigmented melanoma cell line Mel-J were studied using colony formation assay. The RBE values were determined using both a gamma ray source, and the neutron beam from the Nuclear Reactor of the National Atomic Energy Commission (RA-3). For the determination of the RBE, cells were irradiated with increasing doses of both sources, between 1 and 8 Gy; and for the determination of CBE factors, the cells were pre-incubated with BPA before irradiation. Afterwards, the cell surviving fraction (SF) was determined for each treatment. Results: Marked differences were observed between both cell lines. Mel-J cells were more radioresistant than the M8 cell line. The clonogenic assays showed that for a SF of 1%, the RBE values were 1.3 for M8 cells and 1.5 for Mel-J cells. Similarly, the CBE values for a 1% SF were 2.1 for M8 and 3 for Mel-J cell lines. For the endpoint of 0.1% of SF the RBE values obtained were 1.2 for M8 and 1.4 for Mel-J cells. Finally, CBE values calculated for a 0.1% were 2 and 2.6 for M8 and Mel-J cell lines respectively. In order to estimate the uptake of the non-radioactive isotope Boron 10 (10B), a neutron induced autoradiographic technique was performed showing discrepancies in 10B uptake between both cell lines. Conclusions: These obtained in vitro results are the first effectiveness factors determined for human melanoma at the RA-3 nuclear reactor and show that BNCT dosimetry planning for patients could be successfully performed using these new factors.
publishDate 2014
dc.date.none.fl_str_mv 2014-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/35931
Rossini, Andrés Eugenio; Dagrosa, María Alejandra; Portu, Agustina Mariana; Saint Martin, María Laura Gisela; Thorp, Silvia Inés; et al.; Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines; Taylor & Francis Ltd; International Journal Of Radiation Biology; 91; 1; 8-2014; 81-89
0955-3002
CONICET Digital
CONICET
url http://hdl.handle.net/11336/35931
identifier_str_mv Rossini, Andrés Eugenio; Dagrosa, María Alejandra; Portu, Agustina Mariana; Saint Martin, María Laura Gisela; Thorp, Silvia Inés; et al.; Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines; Taylor & Francis Ltd; International Journal Of Radiation Biology; 91; 1; 8-2014; 81-89
0955-3002
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3109/09553002.2014.942013
info:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/full/10.3109/09553002.2014.942013
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis Ltd
publisher.none.fl_str_mv Taylor & Francis Ltd
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269199762718720
score 13.13397

Publicaciones similares